Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Pertuzumab“
Suchtreffer
Begriffe & Kennungen
Phesgo · 4.8 · In the APHINITY trial, a higher incidence of diarrhoea was reported in the pertuzumab-treated arm (71.2 %) com
Eintrag öffnenPhesgo · 4.8 · In the APHINITY trial, febrile neutropenia occurred in 12.1 % of pertuzumab-treated patients and 11.1 % of pla
Eintrag öffnenPhesgo · 4.8 · In the APHINITY trial, the adverse reaction of rash occurred in 25.8 % of patients in pertuzumab arm vs. 20.3
Eintrag öffnenPhesgo · 4.8 · In the FEDERICA study, the incidence of treatment-emergent anti-pertuzumab and anti-trastuzumab antibodies was
Eintrag öffnenPhesgo · 4.8 · In the NEOSPHERE trial, 8.4 % of patients treated with neoadjuvant pertuzumab, trastuzumab and docetaxel exper
Eintrag öffnenPhesgo · 4.8 · In the NEOSPHERE trial, diarrhoea occurred in 45.8 % of patients treated with neoadjuvant pertuzumab, trastuzu
Eintrag öffnenPhesgo · 4.8 · In the NEOSPHERE trial, rash occurred in 40.2 % of patients treated with neoadjuvant pertuzumab, trastuzumab a
Eintrag öffnenPhesgo · 4.8 · In the neoadjuvant trial NEOSPHERE, in which patients received four cycles of pertuzumab as neoadjuvant treatm
Eintrag öffnenPhesgo · 4.8 · In the pivotal trial CLEOPATRA in metastatic breast cancer, diarrhoea occurred in 68.4 % of pertuzumab-treated
Eintrag öffnenPhesgo · 4.8 · In the pivotal trial CLEOPATRA in metastatic breast cancer, rash occurred in 51.7 % of pertuzumab-treated pati
Eintrag öffnenPhesgo · 4.8 · Pertuzumab intravenous in combination with trastuzumab and chemotherapy
Eintrag öffnenPhesgo · 4.8 · Pertuzumab+trastuzumab Phesgo with Phesgo monotherapy chemotherapy
Eintrag öffnenPhesgo · 4.8 · Pertuzumab+trastuzumab Phesgo with Phesgo monotherapy chemotherapy
Eintrag öffnenPhesgo · 4.8 · Pertuzumab+trastuzumab Phesgo with Phesgo monotherapy chemotherapy
Eintrag öffnenPhesgo · 4.8 · Pertuzumab+trastuzumab Phesgo with Phesgo monotherapy chemotherapy
Eintrag öffnenPhesgo · 4.8 · Study MO40628 investigated the safety of switching between intravenous pertuzumab and trastuzumab and Phesgo s
Eintrag öffnenPhesgo · 4.8 · Switching treatment from intravenous pertuzumab and trastuzumab to Phesgo (or vice versa)
Eintrag öffnenPhesgo · 4.8 · Table 2 Summary of ADRs in patients treated with pertuzumab, trastuzumab in pivotal clinical trials^, ^^, and
Eintrag öffnenPhesgo · 4.8 · Table 2 presents, in the first column, ADRs that have been reported in association with the use of pertuzumab
Eintrag öffnenPhesgo · 4.8 · The safety of pertuzumab in combination with trastuzumab has been evaluated in 3 834 patients with HER2-positi
Eintrag öffnen